News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
Marzocchi Pompe’s Repurchase Falls Short of Signal Level, Shows Limited Insider Confidence
101 finance·2026/03/27 19:48
Vimi Fasteners’ Recovery Fueled by Debt Relies on Consistent Increase in Orders and Return of Capital
101 finance·2026/03/27 19:48
S&P 500's "Cheap Risk" Era Is Over—Geopolitical Volatility Could Force a Price Reset
101 finance·2026/03/27 19:48
Alchemy Pay in 2025: Examining On-Ramp Expansion and Strategic Growth Trends
101 finance·2026/03/27 19:48
AI and Stablecoin Flow Trends Remain Strong Despite Crypto Market Decline
101 finance·2026/03/27 19:48
Indonesia: Inflation pressures from Oil and festivals – DBS
101 finance·2026/03/27 19:48
EM stocks might have factored in an ideal 2026 scenario—Will the valuation cushion remain intact?
101 finance·2026/03/27 19:42
$ RKLB might go for deeper correction targeting 50 -54 $
TradingView·2026/03/27 19:42
A Frantic Japan Weighs Selling Oil to Support the Plummeting Yen
101 finance·2026/03/27 19:42
Flash
19:32
Eli Lilly announced that its combination therapy of Taltz and Zepbound achieved the primary endpoint and all key secondary endpoints in a 36-week study period, with data showing that this combination therapy was statistically significantly superior to Taltz monotherapy.This groundbreaking achievement highlights the synergistic effect of combination therapy, providing new clinical evidence for the treatment of related diseases. A comprehensive analysis of the research data will further support the prospects for the application of this therapy.
19:32
Incyte presented the latest positive 54-week data on its investigational drug Povorcitinib for the treatment of hidradenitis suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting.These delayed but important breakthrough research results further validate the long-term efficacy and safety of this therapy, bringing new hope to patients.
19:31
MoonLake Immunotherapeutics officially released the 40-week key data from the phase III clinical trial of its innovative drug Sonelokimab for the treatment of moderate to severe hidradenitis suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting.The results announced this time further validate the drug’s long-lasting efficacy and favorable safety profile, offering new hope for patients’ treatment.